Clinical Advisor2h
FDA Delays Final Approval of Novavax COVID Vaccine
The decision had been expected by April 1, but the agency now says it needs more information before moving forward.
Zacks Investment Research on MSN10h
Novavax (NVAX) Soars 11.4%: Is Further Upside Left in the Stock?
Novavax NVAX shares soared 11.4% in the last trading session to close at $6.24. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...
Health and Me on MSN1d
FDA Delays Approval Of Novavax COVID-19 Vaccine
The delay follows leadership changes within the FDA. Dr. Scott Steele has been appointed acting director of the agency’s ...
Novavax, Inc. (NVAX): Among Unstoppable Stocks That Could Double Your Money
We recently published a list of 10 Unstoppable Stocks That Could Double Your Money. In this article, we are going to take a ...
Ousted vaccine official says Kennedy sought data to justify anti-science stance, WSJ reports
Peter Marks, the FDA's top vaccine official ousted by Robert F. Kennedy Jr. said the U.S. health secretary's team sought ...
Fierce Pharma3d
FDA staff cuts could disrupt drug reviews, putting agency's critical funding programs at risk: reports
Massive cuts at the FDA have hit staff tied to drug reviews and user fees, putting future approvals in jeopardy, according to ...
FDA delay on Novavax vaccine approval could be bellwether for vaccine sector: BofAS
The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has ...
FDA delays full approval of Novavax COVID-19 vaccine even though it was on track for clearance
The FDA has delayed granting full approval of Novavax's COVID-19 vaccine despite it being on track to be cleared until ...
Medical Marketing & Media3d
Rx Rundown: Novo Nordisk, Merck, Eli Lilly and more
Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...
Fierce Pharma3d
Amid FDA tumult, agency misses decision deadline on Novavax's COVID shot
Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...
Novavax’s Covid vaccine delayed in FDA review
Novavax started the week hoping the FDA would issue a full approval of its Covid vaccine. But the decision never came.
Despite Headwinds, Biotech Sell-Off Could Offer Buying Opportunity: Analyst
Biotech stocks face a tough 2025 with SMid-cap losses up to 40% YTD. BofA cites FDA changes, tariffs, and capital struggles but notes potential opportunities.